US pharmacy deals could cut costs of AbbVie and Gilead's HCV treatments

January 6, 2015 2:24 PM

17 0

A number of new drugs for the estimated 3.2 million people in the US living with chronic Hepatitis C virus infection have been launched over the past year, with Abbvie’s drug, Viekira Pak, the latest following its approval by the US Food and Drug Administration (FDA) last month.

The drug combines three active pharmaceutical ingredients (API): an NS5A inhibitor, ombitasvir; NS3/4A protease inhibitor, paritaprevir; and non-nucleoside NS5B polymerase inhibitor, ritonavir.

Also read: Tony Hale says Julia Louis-Dreyfus is just about ready to return to ‘Veep’ following cancer treatment

Read more

To category page